Effect of a Behavioral Intervention to Increase Vegetable Consumption on Cancer Progression Among Men With Early-Stage Prostate Cancer: The MEAL Randomized Clinical Trial | Lifestyle Behaviors | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.173.234.169. Please contact the publisher to request reinstatement.
1.
Resnick  MJ, Lacchetti  C, Bergman  J,  et al.  Prostate cancer survivorship care guideline: American Society of Clinical Oncology Clinical Practice Guideline endorsement.  J Clin Oncol. 2015;33(9):1078-1085. doi:10.1200/JCO.2014.60.2557PubMedGoogle ScholarCrossref
2.
Brooks  JD, Paton  VG, Vidanes  G.  Potent induction of phase 2 enzymes in human prostate cells by sulforaphane.  Cancer Epidemiol Biomarkers Prev. 2001;10(9):949-954.PubMedGoogle Scholar
3.
Nordström  T, Van Blarigan  EL, Ngo  V,  et al.  Associations between circulating carotenoids, genomic instability and the risk of high-grade prostate cancer.  Prostate. 2016;76(4):339-348. doi:10.1002/pros.23125PubMedGoogle ScholarCrossref
4.
Zu  K, Mucci  L, Rosner  BA,  et al.  Dietary lycopene, angiogenesis, and prostate cancer: a prospective study in the prostate-specific antigen era.  J Natl Cancer Inst. 2014;106(2):djt430. doi:10.1093/jnci/djt430PubMedGoogle Scholar
5.
Frattaroli  J, Weidner  G, Dnistrian  AM,  et al.  Clinical events in prostate cancer lifestyle trial: results from two years of follow-up.  Urology. 2008;72(6):1319-1323. doi:10.1016/j.urology.2008.04.050PubMedGoogle ScholarCrossref
6.
Ornish  D, Lin  J, Chan  JM,  et al.  Effect of comprehensive lifestyle changes on telomerase activity and telomere length in men with biopsy-proven low-risk prostate cancer: 5-year follow-up of a descriptive pilot study.  Lancet Oncol. 2013;14(11):1112-1120. doi:10.1016/S1470-2045(13)70366-8PubMedGoogle ScholarCrossref
7.
Cooperberg  MR, Carroll  PR.  Trends in management for patients with localized prostate cancer, 1990-2013.  JAMA. 2015;314(1):80-82. doi:10.1001/jama.2015.6036PubMedGoogle ScholarCrossref
8.
Bul  M, Zhu  X, Valdagni  R,  et al.  Active surveillance for low-risk prostate cancer worldwide: the PRIAS study.  Eur Urol. 2013;63(4):597-603. doi:10.1016/j.eururo.2012.11.005PubMedGoogle ScholarCrossref
9.
Klotz  L, Vesprini  D, Sethukavalan  P,  et al.  Long-term follow-up of a large active surveillance cohort of patients with prostate cancer.  J Clin Oncol. 2015;33(3):272-277. doi:10.1200/JCO.2014.55.1192PubMedGoogle ScholarCrossref
10.
Tosoian  JJ, Trock  BJ, Landis  P,  et al.  Active surveillance program for prostate cancer: an update of the Johns Hopkins experience.  J Clin Oncol. 2011;29(16):2185-2190. doi:10.1200/JCO.2010.32.8112PubMedGoogle ScholarCrossref
11.
Welty  CJ, Cowan  JE, Nguyen  H,  et al.  Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer.  J Urol. 2015;193(3):807-811. doi:10.1016/j.juro.2014.09.094PubMedGoogle ScholarCrossref
12.
Hamdy  FC, Donovan  JL, Lane  JA,  et al; ProtecT Study Group.  10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer.  N Engl J Med. 2016;375(15):1415-1424. doi:10.1056/NEJMoa1606220PubMedGoogle ScholarCrossref
13.
Parsons  JK, Pierce  JP, Mohler  J,  et al.  A randomized trial of diet in men with early stage prostate cancer on active surveillance: rationale and design of the Men’s Eating and Living (MEAL) Study (CALGB 70807 [Alliance]).  Contemp Clin Trials. 2014;38(2):198-203. doi:10.1016/j.cct.2014.05.002PubMedGoogle ScholarCrossref
14.
Parsons  JK, Newman  VA, Mohler  JL, Pierce  JP, Flatt  S, Marshall  J.  Dietary modification in patients with prostate cancer on active surveillance: a randomized, multicentre feasibility study.  BJU Int. 2008;101(10):1227-1231. doi:10.1111/j.1464-410X.2007.07365.xPubMedGoogle ScholarCrossref
15.
National Cancer Institute. Cancer therapy evaluation program instructions and guidelines version 3.0, release 5. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/cdus_ig_3r5.pdf. Published January 11, 2011. Accessed September 12, 2019.
16.
Humphrey  PA, Moch  H, Cubilla  AL, Ulbright  TM, Reuter  VE.  The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: prostate and bladder tumours.  Eur Urol. 2016;70(1):106-119. doi:10.1016/j.eururo.2016.02.028PubMedGoogle ScholarCrossref
17.
Epstein  JI, Amin  MB, Reuter  VE, Humphrey  PA.  Contemporary Gleason grading of prostatic carcinoma: an update with discussion on practical issues to implement the 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma.  Am J Surg Pathol. 2017;41(4):e1-e7. doi:10.1097/PAS.0000000000000820PubMedGoogle ScholarCrossref
18.
Pierce  JP, Natarajan  L, Caan  BJ,  et al.  Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women’s Healthy Eating and Living (WHEL) randomized trial.  JAMA. 2007;298(3):289-298. doi:10.1001/jama.298.3.289PubMedGoogle ScholarCrossref
19.
Prostate Cancer Foundation. Prostate cancer diet. https://www.pcf.org/patient-resources/living-prostate-cancer/prostate-cancer-diet/. Accessed September 12, 2019.
20.
Freedman  LS.  Tables of the number of patients required in clinical trials using the logrank test.  Stat Med. 1982;1(2):121-129. doi:10.1002/sim.4780010204PubMedGoogle ScholarCrossref
21.
Klotz  L, Zhang  L, Lam  A, Nam  R, Mamedov  A, Loblaw  A.  Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer.  J Clin Oncol. 2010;28(1):126-131. doi:10.1200/JCO.2009.24.2180PubMedGoogle ScholarCrossref
22.
Bang  H, Jung  SH, George  SL.  Sample size calculation for simulation-based multiple-testing procedures.  J Biopharm Stat. 2005;15(6):957-967. doi:10.1080/10543400500265710PubMedGoogle ScholarCrossref
23.
Diggle  PJ, Heagerty  PJ, Liang  KY, Zeger  SL.  Analysis of Longitudinal Data. Oxford, UK: Clarendon Press; 1996.
24.
Thomson  CA, Ravia  J.  A systematic review of behavioral interventions to promote intake of fruit and vegetables.  J Am Diet Assoc. 2011;111(10):1523-1535. doi:10.1016/j.jada.2011.07.013PubMedGoogle ScholarCrossref
25.
Sfanos  KS, Markowski  MC, Peiffer  LB,  et al.  Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies.  Prostate Cancer Prostatic Dis. 2018;21(4):539-548. doi:10.1038/s41391-018-0061-xPubMedGoogle ScholarCrossref
26.
Newton  RU, Kenfield  SA, Hart  NH,  et al.  Intense Exercise for Survival Among Men With Metastatic Castrate-Resistant Prostate Cancer (INTERVAL-GAP4): a multicentre, randomised, controlled phase III study protocol.  BMJ Open. 2018;8(5):e022899. doi:10.1136/bmjopen-2018-022899PubMedGoogle Scholar
27.
Gardner  JR, Livingston  PM, Fraser  SF.  Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review.  J Clin Oncol. 2014;32(4):335-346. doi:10.1200/JCO.2013.49.5523PubMedGoogle ScholarCrossref
28.
Klein  EA, Thompson  IM  Jr, Tangen  CM,  et al.  Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).  JAMA. 2011;306(14):1549-1556. doi:10.1001/jama.2011.1437PubMedGoogle ScholarCrossref
29.
Gaziano  JM, Glynn  RJ, Christen  WG,  et al.  Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians’ Health Study II randomized controlled trial.  JAMA. 2009;301(1):52-62. doi:10.1001/jama.2008.862PubMedGoogle ScholarCrossref
30.
Manson  JE, Cook  NR, Lee  IM,  et al; VITAL Research Group.  Marine n-3 fatty acids and prevention of cardiovascular disease and cancer.  N Engl J Med. 2019;380(1):23-32. doi:10.1056/NEJMoa1811403PubMedGoogle ScholarCrossref
31.
Manson  JE, Cook  NR, Lee  IM,  et al; VITAL Research Group.  Vitamin D supplements and prevention of cancer and cardiovascular disease.  N Engl J Med. 2019;380(1):33-44. doi:10.1056/NEJMoa1809944PubMedGoogle ScholarCrossref
32.
Meyskens  FL  Jr, Szabo  E.  Diet and cancer: the disconnect between epidemiology and randomized clinical trials.  Cancer Epidemiol Biomarkers Prev. 2005;14(6):1366-1369. doi:10.1158/1055-9965.EPI-04-0666PubMedGoogle ScholarCrossref
33.
Ioannidis  JPA.  The challenge of reforming nutritional epidemiologic research.  JAMA. 2018;320(10):969-970. doi:10.1001/jama.2018.11025PubMedGoogle ScholarCrossref
34.
Trepanowski  JF, Ioannidis  JPA.  Perspective: limiting dependence on nonrandomized studies and improving randomized trials in human nutrition research: why and how.  Adv Nutr. 2018;9(4):367-377. doi:10.1093/advances/nmy014PubMedGoogle ScholarCrossref
35.
Schoenfeld  JD, Ioannidis  JP.  Is everything we eat associated with cancer? a systematic cookbook review.  Am J Clin Nutr. 2013;97(1):127-134. doi:10.3945/ajcn.112.047142PubMedGoogle ScholarCrossref
Original Investigation
January 14, 2020

Effect of a Behavioral Intervention to Increase Vegetable Consumption on Cancer Progression Among Men With Early-Stage Prostate Cancer: The MEAL Randomized Clinical Trial

Author Affiliations
  • 1Department of Urology, UC San Diego Moores Comprehensive Cancer Center and VA San Diego Healthcare System, La Jolla, California
  • 2Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota
  • 3Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, New York
  • 4Comprehensive Cancer Center, Department of Medicine, The Ohio State University College of Medicine, Columbus
  • 5Department of Pathology, University of California, San Diego, La Jolla
  • 6Division of Urology, Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical School, Boston, Massachusetts
  • 7Division of Biostatistics and Bioinformatics, Department of Family Medicine and Public Health and UC San Diego Moores Comprehensive Cancer Center, La Jolla, California
  • 8Alliance Central Protocol Operations, University of Chicago, Chicago, Illinois
  • 9Moores Cancer Center, Department of Family Medicine and Public Health, University of California, San Diego, La Jolla
  • 10Department of Urology, Naval Medical Center San Diego, San Diego, California
  • 11Menorah Medical Center, Midwest Oncology Associates, Overland Park, Kansas
  • 12Siteman Cancer Center, Department of Radiation Oncology, Washington University, St Peters, Missouri
  • 13UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California
  • 14Memorial Sloan Kettering Cancer Center, New York, New York
  • 15Department of Prevention and Population Sciences, Roswell Park Comprehensive Cancer Center, Buffalo, New York
JAMA. 2020;323(2):140-148. doi:10.1001/jama.2019.20207
Visual Abstract. Effect of a Behavioral Intervention to Increase Vegetable Consumption on Cancer Progression Among Men With Early-Stage Prostate Cancer
Effect of a Behavioral Intervention to Increase Vegetable Consumption on Cancer Progression Among Men With Early-Stage Prostate Cancer
Key Points

Question  Does a behavioral intervention promoting vegetable consumption decrease cancer progression in men with early-stage prostate cancer on active surveillance?

Findings  In this randomized clinical trial that included 478 patients, there was no significant difference in prostate cancer progression over 2 years among men who participated in a counseling program that encouraged consumption of leafy green, carotenoid, and cruciferous vegetables compared with controls (hazard ratio, 0.96).

Meaning  A behavioral intervention that increased vegetable consumption did not significantly reduce the risk of prostate cancer progression among men with early-stage disease.

Abstract

Importance  Guidelines endorsing vegetable-enriched diets to improve outcomes for prostate cancer survivors are based on expert opinion, preclinical studies, and observational data.

Objective  To determine the effect of a behavioral intervention that increased vegetable intake on cancer progression in men with early-stage prostate cancer.

Design, Setting, and Participants  The Men’s Eating and Living (MEAL) Study (CALGB 70807 [Alliance]) was a randomized clinical trial conducted at 91 US urology and medical oncology clinics that enrolled 478 men aged 50 to 80 years with biopsy-proven prostate adenocarcinoma (International Society of Urological Pathology grade group = 1 in those <70 years and ≤2 in those ≥70 years), stage cT2a or less, and serum prostate-specific antigen (PSA) level less than 10 ng/mL. Enrollment occurred from January 2011 to August 2015; 24-month follow-up occurred from January 2013 to August 2017.

Interventions  Patients were randomized to a counseling behavioral intervention by telephone promoting consumption of 7 or more daily vegetable servings (MEAL intervention; n = 237) or a control group, which received written information about diet and prostate cancer (n = 241).

Main Outcomes and Measures  The primary outcome was time to progression; progression was defined as PSA level of 10 ng/mL or greater, PSA doubling time of less than 3 years, or upgrading (defined as increase in tumor volume or grade) on follow-up prostate biopsy.

Results  Among 478 patients randomized (mean [SD] age, 64 [7] years; mean [SD] PSA level, 4.9 [2.1] ng/mL), 443 eligible patients (93%) were included in the primary analysis. There were 245 progression events (intervention: 124; control: 121). There were no significant differences in time to progression (unadjusted hazards ratio, 0.96 [95% CI, 0.75 to 1.24]; adjusted hazard ratio, 0.97 [95% CI, 0.76 to 1.25]). The 24-month Kaplan-Meier progression-free percentages were 43.5% [95% CI, 36.5% to 50.6%] and 41.4% [95% CI, 34.3% to 48.7%] for the intervention and control groups, respectively (difference, 2.1% [95% CI, −8.1% to 12.2%]).

Conclusions and Relevance  Among men with early-stage prostate cancer managed with active surveillance, a behavioral intervention that increased vegetable consumption did not significantly reduce the risk of prostate cancer progression. The findings do not support use of this intervention to decrease prostate cancer progression in this population, although the study may have been underpowered to identify a clinically important difference.

Trial Registration  ClinicalTrials.gov Identifier: NCT01238172

×